



ICSGLOBAL LIMITED

ASX RELEASE – 27 February 2017

First Half Results: Revenue up 8% in GBP terms, Pause in AUD profit growth primarily due to FX impacts, 2016 Dividend Paid, New opportunities being reviewed

- H1 2017 underlying profit of \$200,763, down 65% on H1 2016, primarily attributable to the FX impact following the Brexit result. If the H1 2017 average and closing FX rates were the same as H1 2016 FX rates, the result would have been \$0.22 million stronger.
- H1 2017 sales revenue of \$2,145,640 down 14% on H1 2016, however in GBP terms was up 8% to £1,262,778
- Payment of an annual dividend of 3.5 cents per share (\$370,441) for the 2016 year in October 2016
- The interim dividend has been suspended for this 2017 year as ICS is currently reviewing several potential acquisitions/investments
- Maintain 2017 full year guidance of net profit after tax expected to be in the range of \$700,000 to \$1.1 million (subject to FX movement)
- MBC highlights include:
 - Revenue up 8% in GBP terms and profit down 12% in GBP terms
 - On the MBC revenue side, a large clinic that was signed up during H1 2017 only commenced operations in December 2016, which was later than expected. Increased revenue is expected in H2 2017
 - Expenses in the GBP increased 17% due to increased staff costs and one off IT costs. Staff costs increased before the large clinic came on line. After one off IT costs are adjusted, there would have been GBP profit growth
 - A new medical indemnity insurance product was launched in Q4 2016 as part of the strategy of providing quality ancillary services to our client base which will generate incremental recurring revenue for MBC
 - MBC continued to invest in infrastructure, personnel and IT to grow the clinic division which is an incremental business targeting different segments of our market. The increased costs, particularly in IT, have been incurred due to the need to ensure that the IT platform has no single point of failure and also increased platform speed to meet the demands of this additional segment
 - MBC have appointed a new General Manager in January 2017 to assist the existing management team to further grow the business

H1 2017 result

H1 2017 underlying profit of \$200,763 in AUD was down 65% on H1 2016. As was advised at the November 2016 AGM, the main factor impacting on the profit was the significant adverse FX movement in GBP following the Brexit result. If the H1 2017 average and closing FX rates were the same as H1 2016 FX rates, the result would have been \$0.22 million stronger.

Key FX impacts were :

- The translation of monthly earnings to AUD (\$0.13 million)
- The translation of the GBP bank account balance to AUD (\$0.09 million)



Pleasingly H1 2017 sales revenue for MBC in GBP increased 8% to £1,262,778 (\$2,145,640 in AUD terms down 14% on H1 2016). Profit in GBP terms for MBC decreased 12% due to a 17% increase in costs attributable to increased staff costs and one-off IT costs. Staff costs increased to accommodate a large clinic which came on line in December 2016. After one-off IT costs are adjusted, the GBP profit would have increased.

The Board expects to see an improved financial performance in H2 2017.

Full financial details of the half-year result can be found in the accompanying Appendix 4D and Interim Report.

ICS Group	6 months to December 2015	6 months to December 2016	Change (%)
	AUD	AUD	
Revenue from Operations	2,487,293	2,145,640	-13.70%
Revenue from Operations GBP	£1,169,164	£1,262,778	+8.01%
Profit after Tax	577,354	200,763	-65.2%
Profit after Tax UK Business in GBP	£348,886	£307,090	-11.98%
	Balance 30 June 2016	Balance 31 December 2016	Change
	AUD	AUD	%
Cash and Equivalents (excluding UK Doctors' funds)	1,366,984	1,205,483	-11.8%

Dividends

During the half-year, the Board was pleased to be able to pay another ICS dividend of 3.5 cents per share (\$370,441) for the 2016 year.

The 2017 year interim dividend has been suspended as ICS is currently reviewing two potential acquisitions/investments.

Guidance

The Board re-affirms its previous 2017 full year guidance of net profit after tax and expects it to be in the range of \$700,000 to \$1.1m for the 2017 year¹.

Cash balance

Cash and equivalents (excluding cash held in the UK on behalf of Doctors) as at 31 December 2016 was \$1,205,483 which was a decrease of 11% on the June 2016 reporting balance of \$1,366,984.

¹ Subject to FX rates.



The decrease in corporate cash during H1 2017 was primarily attributable to:

- A \$141,678 investment in the MBC IT platform to further enhance the operational integrity and client experience. Given the growth in MBC revenue and customers, the Board agreed to the improvements in the IT system capabilities
- Dividends of \$370,441 that were paid in October 2016
- The balance is attributable to movements in working capital.

UK Operations

MBC has been able to grow revenue by 8% in GBP terms, however with increased costs this has resulted in profit reduction of 12% in GBP terms. As mentioned previously, the increased costs are primarily attributable to increased staff costs and one off IT costs. Staff costs increased to prepare for a large clinic came on line in December 2016. After one off IT costs are adjusted, the GBP profit would have increased.

On the MBC revenue side, a large clinic that was signed up during H1 2017 only commenced operations in December 2016, which was later than expected. Increased revenue is expected in H2 2017.

MBC has agreed to support the marketing of a new medical indemnity insurance product in Q4 2016 as part of the strategy of providing quality ancillary services to our client base; this will generate incremental recurring revenue for MBC, starting in H2 2017.

MBC continued to invest in infrastructure, personnel and IT to grow the clinic division which is an incremental business targeting different segments of our market. The increased costs, particularly in IT, have been incurred due to the need to ensure that the IT platform has no single point of failure and increased speed to meet the demands of this segment.

MBC have appointed a new General Manager in January 2017 to assist the existing management team to further grow the business.

Australian corporate cash costs

The corporate cash costs in Australia are running around \$450,000 on an annualised basis, including administration costs that were incurred for the dividend payment. The H1 2017 Australian corporate cash costs were \$217,719.

Future activities

OpenLearning

The Board is pleased to advise that OpenLearning has made substantial progress on several fronts including:

- On the commercial front, OpenLearning continues to sign up commercial clients offering online courses for students on a subscription model plus upfront payments
- In the higher education sector in Malaysia:
 - OpenLearning has over 250,000 students who have now enrolled in courses on from 26 universities and 34 public polytechnics across the country
 - Partnered with Media Prima/New Straits Times Press to launch a series of exam preparation courses for school students on a subscription payment model
- In Australia, OpenLearning:
 - Continued our work with key Australian Federal Government and higher education clients throughout FY16 to expand the number of courses and students
 - Launched Learn.com.au in the Vocational Education and Training sector in partnership with Hunter TAFE and Innovation and Business Skills Australia to offer the first VET courses in the country where students can learn for free and pay only if they want a certification



- Signed a campus-wide license agreement with a leading Australian university to more widely deploy OpenLearning across campus

ICS has a \$0.293 million (at cost) investment in OpenLearning, for approximately a 3% stake in the company as part of OpenLearning's successful round of fund-raising. Based on its recent performance, OpenLearning is in a favourable position and is seeking to raise \$10 million at valuation of the business at a multiple to ICS's investment.

Other Opportunities

The Board is in active negotiation on several acquisitions/investments that are in the healthcare space. The Board will update the market on any progress in relation to these opportunities.

We thank you for your on-going support.

For and on behalf of the Board.

A handwritten signature in black ink, appearing to be 'Kevin Barry', with a large, stylized loop at the end.

Kevin Barry
Chairman

1. Company details

Name of entity:	ICSGlobal Limited
ABN:	72 073 695 584
Reporting period:	For the half-year ended 31 December 2016
Previous period:	For the half-year ended 31 December 2015

2. Results for announcement to the market

			\$
Revenues from ordinary activities	down	13.7% to	2,145,640
Profit from ordinary activities after tax attributable to the owners of ICSGlobal Limited	down	65.2% to	200,763
Profit for the half-year attributable to the owners of ICSGlobal Limited	down	65.2% to	200,763

Dividends

	Amount per security Cents	Franked amount per security Cents
Final dividend for the year ended 30 June 2016 (unfranked) was paid on 28 October 2016	3.500	-

Comments

The profit for the consolidated entity after providing for income tax amounted to \$200,763 (31 December 2015: \$577,354).

Further commentary on the business operations and developments by directors are contained in the attached letter from the Chairman.

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	24.64	24.61

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

6. Dividend reinvestment plans

Not applicable.

7. Foreign entities

Details of origin of accounting standards used in compiling the report:

Not applicable.

8. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report.

9. Attachments

Details of attachments (if any):

The Interim Report of ICSGlobal Limited for the half-year ended 31 December 2016 is attached.

10. Signed



Signed _____

Date: 27 February 2017

Kevin Barry
Chairman
Sydney

ICSGlobal Limited

ABN 72 073 695 584

Interim Report - 31 December 2016

The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'consolidated entity') consisting of ICSGlobal Limited (referred to hereafter as the 'company' or 'parent entity') and the entities it controlled at the end of, or during, the half-year ended 31 December 2016.

Directors

The following persons were directors of ICSGlobal Limited during the whole of the financial half-year and up to the date of this report, unless otherwise stated:

Kevin Barry - Chairman
Gregory Quirk
Victor Shkolnik
James Canning-Ure

Principal activities

The principal activities of the consolidated entity during the financial half-year were the operations of an investment holding company in Australia and the provision of medical billing services, specifically in the United Kingdom ('UK').

Review of operations

The profit for the consolidated entity after providing for income tax amounted to \$200,763 (31 December 2015: \$577,354).

Further commentary on the business operations and developments by directors are contained in the attached letter from the Chairman.

Significant changes in the state of affairs

There were no significant changes in the state of affairs of the consolidated entity during the financial half-year.

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this directors' report.

This report is made in accordance with a resolution of directors, pursuant to section 306(3)(a) of the Corporations Act 2001.

On behalf of the directors



Kevin Barry
Chairman

27 February 2017
Sydney

**ICS GLOBAL LIMITED
ABN 72 073 695 584**

**AUDITOR'S INDEPENDENCE DECLARATION
UNDER SECTION 307C OF THE CORPORATIONS ACT 2001
TO THE DIRECTORS OF 72 073 695 584**

SYDNEY

Level 40
2 Park Street
Sydney NSW 2000
Australia

GPO Box 3555
Sydney NSW 2001


Ph: (612) 9263 2600
Fx: (612) 9263 2800

I declare that, to the best of my knowledge and belief, during the half-year ended 31 December 2016 there have been no contraventions of:

- (i) the auditor independence requirements as set out in the Corporations Act 2001 in relation to the review; and
- (ii) any applicable code of professional conduct in relation to the review.

Hall Chadwick

Hall Chadwick
Level 40, 2 Park Street
Sydney NSW 2000



DREW TOWNSEND

Partner

Date: 27 February 2017

A member of AGN
International Ltd, a
worldwide association
of separate and
independent
accounting
and consulting firms

www.hallchadwick.com.au

SYDNEY • NEWCASTLE • PARRAMATTA • PENRITH • MELBOURNE • PERTH • BRISBANE • GOLD COAST • DARWIN

Statement of profit or loss and other comprehensive income	4
Statement of financial position	5
Statement of changes in equity	6
Statement of cash flows	7
Notes to the financial statements	8
Directors' declaration	13
Independent auditor's review report to the members of ICSGlobal Limited	14

General information

The financial statements cover ICSGlobal Limited as a consolidated entity consisting of ICSGlobal Limited and the entities it controlled at the end of, or during, the half-year. The financial statements are presented in Australian dollars, which is ICSGlobal Limited's functional and presentation currency.

ICSGlobal Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is:

Suite 3.03
20 Bond Street
Sydney, NSW 2000

A description of the nature of the consolidated entity's operations and its principal activities are included in the directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of directors, on 27 February 2017. The directors have the power to amend and reissue the financial statements.

ICSGlobal Limited
Statement of profit or loss and other
comprehensive income
For the half-year ended 31 December 2016



	Note	Consolidated 31/12/2016 \$	Consolidated 31/12/2015 \$
Revenue	3	2,145,640	2,487,293
Expenses			
Employee benefits expenses		(984,542)	(1,107,126)
External contractor expenses		(67,424)	(51,370)
Directors fees		(70,000)	(60,000)
Occupancy expenses		(118,401)	(131,689)
Depreciation and amortisation expenses		(105,058)	(126,125)
Marketing expenses		(61,744)	(119,056)
Legal fees		(2,668)	(916)
Communication and travel		(10,080)	(27,119)
Postage and stationery		(50,018)	(56,133)
Computer expenses		(22,028)	(25,704)
Net foreign exchange (loss)/gain		(90,310)	1,007
Other expenses		(362,604)	(209,427)
Profit before income tax benefit		200,763	573,635
Income tax benefit		-	3,719
Profit after income tax benefit for the half-year attributable to the owners of ICSGlobal Limited		200,763	577,354
Other comprehensive income			
<i>Items that may be reclassified subsequently to profit or loss</i>			
Foreign currency translation		(47,986)	(39,590)
Other comprehensive income for the half-year, net of tax		(47,986)	(39,590)
Total comprehensive income for the half-year attributable to the owners of ICSGlobal Limited		152,777	537,764
		Cents	Cents
Basic earnings per share	12	1.900	5.474
Diluted earnings per share	12	1.859	5.427

The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

	Note	Consolidated 31/12/2016 \$	Consolidated 30/06/2016 \$
Assets			
Current assets			
Cash and cash equivalents	4	2,630,816	1,994,535
Trade and other receivables	5	584,797	704,166
Total current assets		<u>3,215,613</u>	<u>2,698,701</u>
Non-current assets			
Available-for-sale financial assets		293,900	293,900
Property, plant and equipment		93,834	115,622
Intangibles	6	2,791,336	2,750,080
Deferred tax		650,172	650,172
Total non-current assets		<u>3,829,242</u>	<u>3,809,774</u>
Total assets		<u>7,044,855</u>	<u>6,508,475</u>
Liabilities			
Current liabilities			
Trade and other payables	7	1,619,254	862,698
Income tax		26,595	27,730
Employee benefits		-	12,579
Total current liabilities		<u>1,645,849</u>	<u>903,007</u>
Total liabilities		<u>1,645,849</u>	<u>903,007</u>
Net assets		<u>5,399,006</u>	<u>5,605,468</u>
Equity			
Issued capital	8	34,759,895	34,759,895
Reserves		679,168	715,952
Accumulated losses		(30,040,057)	(29,870,379)
Total equity		<u>5,399,006</u>	<u>5,605,468</u>

The above statement of financial position should be read in conjunction with the accompanying notes

Consolidated	Issued capital \$	Reserves \$	Accumulated losses \$	Total equity \$
Balance at 1 July 2015	34,759,895	884,270	(30,563,323)	5,080,842
Profit after income tax benefit for the half-year	-	-	577,354	577,354
Other comprehensive income for the half-year, net of tax	-	(39,590)	-	(39,590)
Total comprehensive income for the half-year	-	(39,590)	577,354	537,764
<i>Transactions with owners in their capacity as owners:</i>				
Share-based payments	-	2,842	-	2,842
Dividends paid (note 9)	-	-	(263,663)	(263,663)
Balance at 31 December 2015	<u>34,759,895</u>	<u>847,522</u>	<u>(30,249,632)</u>	<u>5,357,785</u>
Consolidated	Issued capital \$	Reserves \$	Accumulated losses \$	Total equity \$
Balance at 1 July 2016	34,759,895	715,952	(29,870,379)	5,605,468
Profit after income tax expense for the half-year	-	-	200,763	200,763
Other comprehensive income for the half-year, net of tax	-	(47,986)	-	(47,986)
Total comprehensive income for the half-year	-	(47,986)	200,763	152,777
<i>Transactions with owners in their capacity as owners:</i>				
Share-based payments	-	11,202	-	11,202
Dividends paid (note 9)	-	-	(370,441)	(370,441)
Balance at 31 December 2016	<u>34,759,895</u>	<u>679,168</u>	<u>(30,040,057)</u>	<u>5,399,006</u>

The above statement of changes in equity should be read in conjunction with the accompanying notes

	Consolidated	
Note	31/12/2016	31/12/2015
	\$	\$
Cash flows from operating activities		
Receipts from customers (inclusive of GST and VAT)	2,678,196	2,925,923
Payments to suppliers and employees (inclusive of GST and VAT)	(1,499,040)	(2,812,791)
Interest received	1,179,156	113,132
	78	266
Net cash from operating activities	1,179,234	113,398
Cash flows from investing activities		
Payments for property, plant and equipment	(7,948)	(2,363)
Payments for intangibles	(139,946)	(260,556)
Net cash used in investing activities	(147,894)	(262,919)
Cash flows from financing activities		
Dividends paid	(370,441)	(263,663)
Net cash used in financing activities	(370,441)	(263,663)
Net increase/(decrease) in cash and cash equivalents	660,899	(413,184)
Cash and cash equivalents at the beginning of the financial half-year	1,994,535	2,637,247
Effects of exchange rate changes on cash and cash equivalents	(24,618)	21,831
Cash and cash equivalents at the end of the financial half-year	4 <u>2,630,816</u>	<u>2,245,894</u>

Note 1. Significant accounting policies

These general purpose financial statements for the interim half-year reporting period ended 31 December 2016 have been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.

These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2016 and any public announcements made by the company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

The principal accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated.

New or amended Accounting Standards and Interpretations adopted

The consolidated entity has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period. The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the consolidated entity during the financial half-year ended 31 December 2016 and are not expected to have any significant impact for the full financial year ending 30 June 2017.

Note 2. Operating segments

Identification of reportable operating segments

The consolidated entity only has one reportable segment being the provision of medical billing services in the UK.

Geographical information

	Sales to external customers		Geographical non-current assets	
	31/12/2016	31/12/2015	31/12/2016	30/06/2016
	\$	\$	\$	\$
Australia	-	-	293,900	293,900
United Kingdom	2,066,329	2,456,821	2,885,170	2,865,702
	<u>2,066,329</u>	<u>2,456,821</u>	<u>3,179,070</u>	<u>3,159,602</u>

The geographical non-current assets above are exclusive of, where applicable, financial instruments, deferred tax assets, post-employment benefits assets and rights under insurance contracts.

Note 3. Revenue

	Consolidated	
	31/12/2016	31/12/2015
	\$	\$
<i>Sales revenue</i>		
Medical billing service	2,066,329	2,456,821
<i>Other revenue</i>		
Interest	78	266
Other revenue	79,233	30,206
	<u>79,311</u>	<u>30,472</u>
Revenue	<u>2,145,640</u>	<u>2,487,293</u>

Note 4. Current assets - cash and cash equivalents

	Consolidated	
	31/12/2016	30/06/2016
	\$	\$
Cash on trust *	1,425,333	627,551
Cash at bank	1,205,483	1,366,984
	<u>2,630,816</u>	<u>1,994,535</u>

* The cash on trust is offset by an equal liability in other payables and it is not for general use of the consolidated entity.

Note 5. Current assets - trade and other receivables

	Consolidated	
	31/12/2016	30/06/2016
	\$	\$
Trade receivables	467,157	585,386
Less: Provision for impairment of receivables	(34,685)	(34,685)
	<u>432,472</u>	<u>550,701</u>
Prepayments	144,063	145,127
VAT and GST receivable	8,262	8,338
	<u>584,797</u>	<u>704,166</u>

Note 6. Non-current assets - intangibles

	Consolidated	
	31/12/2016	30/06/2016
	\$	\$
Goodwill - at cost	2,214,282	2,214,282
Software - at cost	1,150,756	1,050,632
Less: Accumulated amortisation	(573,702)	(514,834)
	<u>577,054</u>	<u>535,798</u>
	<u>2,791,336</u>	<u>2,750,080</u>

Reconciliations

Reconciliations of the written down values at the beginning and end of the current financial half-year are set out below:

Consolidated	Goodwill \$	Software \$	Total \$
Balance at 1 July 2016	2,214,282	535,798	2,750,080
Additions	-	139,946	139,946
Exchange differences	-	(19,089)	(19,089)
Amortisation expense	-	(79,601)	(79,601)
Balance at 31 December 2016	<u>2,214,282</u>	<u>577,054</u>	<u>2,791,336</u>

Note 7. Current liabilities - trade and other payables

	Consolidated	
	31/12/2016	30/06/2016
	\$	\$
Trade payables	46,356	43,873
VAT payable	113,235	143,678
Other payables	1,459,663	675,147
	<u>1,619,254</u>	<u>862,698</u>

Note 8. Equity - issued capital

	Consolidated			
	31/12/2016	30/06/2016	31/12/2016	30/06/2016
	Shares	Shares	\$	\$
Ordinary shares - fully paid	<u>10,584,019</u>	<u>10,546,519</u>	<u>34,759,895</u>	<u>34,759,895</u>

Movements in ordinary share capital

Details	Date	No of shares	Issue price	\$
Balance	1 July 2016	10,546,519		34,759,895
Exercise of performance rights	6 October 2016	<u>37,500</u>	<u>\$0.00</u>	<u>-</u>
Balance	31 December 2016	<u>10,584,019</u>		<u>34,759,895</u>

Options and performance rights

There were 1,500,000 (30 June 2016: 1,500,000) performance rights as at 31 December 2016 which may convert into 75,000 ordinary shares (20:1) if the performance conditions are met.

Note 9. Equity - dividends

Dividends paid during the financial half-year were as follows:

	Consolidated	
	31/12/2016	31/12/2015
	\$	\$
Final dividend for the year ended 30 June 2016 of 3.5 cents per ordinary share paid unfranked (2015: 2.5 cents per ordinary share unfranked)	<u>370,441</u>	<u>263,663</u>

Note 10. Fair value measurement

Fair value hierarchy

The following tables detail the consolidated entity's assets and liabilities, measured or disclosed at fair value, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly

Level 3: Unobservable inputs for the asset or liability

	Level 1 \$	Level 2 \$	Level 3 \$	Total \$
Consolidated - 31/12/2016				
Assets				
Ordinary shares available-for-sale	-	-	293,900	293,900
Total assets	-	-	293,900	293,900

	Level 1 \$	Level 2 \$	Level 3 \$	Total \$
Consolidated - 30/06/2016				
Assets				
Ordinary shares available-for-sale	-	-	293,900	293,900
Total assets	-	-	293,900	293,900

There were no transfers between levels during the financial half-year.

Valuation techniques for fair value measurements categorised within level 2 and level 3
Unquoted investments have been valued using a discounted cash flow model.

Note 11. Contingent liabilities

The consolidated entity had no contingent liabilities at 31 December 2016 and 30 June 2016.

Note 12. Earnings per share

	Consolidated 31/12/2016 \$	Consolidated 31/12/2015 \$
Profit after income tax attributable to the owners of ICSGlobal Limited	200,763	577,354
	Number	Number
Weighted average number of ordinary shares used in calculating basic earnings per share	10,564,250	10,546,519
Adjustments for calculation of diluted earnings per share:		
Performance rights	237,500	92,935
Weighted average number of ordinary shares used in calculating diluted earnings per share	10,801,750	10,639,454
	Cents	Cents
Basic earnings per share	1.900	5.474
Diluted earnings per share	1.859	5.427

Note 13. Events after the reporting period

No matter or circumstance has arisen since 31 December 2016 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.

In the directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes give a true and fair view of the consolidated entity's financial position as at 31 December 2016 and of its performance for the financial half-year ended on that date; and
- there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of directors made pursuant to section 303(5)(a) of the Corporations Act 2001.

On behalf of the directors



Kevin Barry
Chairman

27 February 2017
Sydney

ICS GLOBAL LIMITED**ABN 72 073 695 584****INDEPENDENT AUDITOR'S REVIEW REPORT TO THE MEMBERS OF
ICS GLOBAL LIMITED****SYDNEY**Level 40
2 Park Street
Sydney NSW 2000
AustraliaGPO Box 3555
Sydney NSW 2001Ph: (612) 9263 2600
Fx: (612) 9263 2800**Report on the Interim Financial Report**

We have reviewed the accompanying interim financial report of ICS Global Limited, which comprises the statement of financial position as at 31 December 2016, the statement of profit or loss and other comprehensive income, statement of changes in equity, and statement of cash flows for the period ended on that date, notes comprising a summary of significant accounting policies and other explanatory information and the directors' declaration.

Directors' Responsibility for the Interim Financial Report

The directors of ICS Global Limited are responsible for the preparation of the interim financial report that gives a true and fair view in accordance with Australian Accounting Standards (including Australian Accounting Interpretations) and the Corporations Act 2001 and for such internal control as the directors determine is necessary to enable the preparation of the interim financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express a conclusion on the interim financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410: Review of a Financial Report Performed by the Independent Auditor of the Entity, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the interim financial report is not in accordance with the Corporations Act 2001 including: giving a true and fair view of ICS Global Limited's financial position as at 31 December 2016 and its performance for the period ended on that date, and complying with Accounting Standard AASB 134: Interim Financial Reporting and the Corporations Regulations 2001. As the auditor of ICS Global Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of an interim financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independence

In conducting our review, we have complied with the independence requirements of the Corporations Act 2001.

A member of AGN
International Ltd, a
worldwide association
of separate and
independent
accounting
and consulting firms

www.hallchadwick.com.au**SYDNEY • NEWCASTLE • PARRAMATTA • PENRITH • MELBOURNE • PERTH • BRISBANE • GOLD COAST • DARWIN**

ICS GLOBAL LIMITED
ABN 72 073 695 584

**INDEPENDENT AUDITOR'S REVIEW REPORT TO THE MEMBERS OF
ICS GLOBAL LIMITED**

Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the interim financial report of ICS Global Limited is not in accordance with the Corporations Act 2001 including:

- (i) giving a true and fair view of ICS Global Limited's financial position as at 31 December 2016 and of its performance for the period ended on that date; and
- (ii) complying with AASB 134: Interim Financial Reporting and the Corporations Regulations 2001.



HALL CHADWICK
Level 40, 2 Park Street
Sydney NSW 2000



DREW TOWNSEND
Partner
Dated: 27 February 2017